<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597518</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-12-001</org_study_id>
    <nct_id>NCT01597518</nct_id>
  </id_info>
  <brief_title>Riluzole in Spinal Cord Injury Study</brief_title>
  <acronym>RISCIS</acronym>
  <official_title>A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOSpine North America Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOSpine International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christopher Reeve Paralysis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rick Hansen Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AOSpine North America Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate efficacy and safety of riluzole in the treatment of
      patients with acute SCI. The primary objective is to evaluate the superiority of riluzole, at
      a dose of 2 x 100 mg the first 24 hours followed by 2 x 50 mg for the following 13 days after
      injury, as compared to placebo, in change between 180 days and baseline in motor outcomes as
      measured by International Standards for Neurological Classification of Spinal Cord Injury
      Examination (ISNCSCI) Motor Score, in patients with acute traumatic SCI, presenting to the
      hospital less than 12 hours after injury. Secondary objectives are to evaluate the effects of
      riluzole on overall neurologic recovery, sensory recovery, functional outcomes, quality of
      life outcomes, health utilities, mortality, and adverse events. The working hypothesis is
      that the riluzole treated subjects will experience superior motor, sensory, functional, and
      quality of life outcomes as compared to those receiving placebo, with an acceptable safety
      profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present there are over 1 million people living with Spinal Cord Injury (SCI) in North
      America alone, with annual costs for the acute treatment and chronic care of these patients
      totaling four billion dollars USD. The worldwide prevalence of SCI is unknown, with estimates
      ranging up to 250 million individuals. The incidence of SCI in developed countries has been
      estimated to be between 10 - 40 cases per million inhabitants. In spite of the immense impact
      of SCI at a personal and societal level, an effective and safe pharmacologic treatment for
      SCI, shown to improve neurological and functional outcomes at long-term follow-up, remains
      absent.

      The final degree of neurological tissue destruction that occurs after traumatic SCI is a
      product of both primary and secondary injury mechanisms. The primary mechanical injury to the
      cord initiates a subsequent signaling cascade of deleterious down-stream events, known
      collectively as secondary injury mechanisms. These secondary injury mechanisms include
      ischemia, interstitial and cellular ionic imbalance, free radical formation, glutamatergic
      excitotoxicity, lipid peroxidation and generation of arachidonic acid metabolites. Although
      little can be done from a therapeutic standpoint to correct damage sustained during the
      primary injury, by mitigating the evolution of secondary injury events there is opportunity
      to preserve remnant viable neurological tissue and improve neurologic outcomes. There is
      convincing evidence from the preclinical realm that the pharmacologic agent riluzole
      attenuates certain aspects of the secondary injury cascade leading to diminished neurological
      tissue destruction in animal SCI models. Riluzole, a sodium channel blocking benzothiazole
      anticonvulsant, specifically exerts its neuroprotective effect by helping to maintain
      neuronal cellular ionic balance and by reducing the release of excitotoxic glutamate in the
      post-SCI setting. Several preclinical studies in the rodent SCI model have associated
      administration of riluzole with increased neural tissue preservation at the site of injury,
      in addition to improved behavioral outcomes, in comparison to administration of placebo or
      other sodium channel blocking drugs. In the clinical realm, while riluzole has not been
      studied extensively in the context of SCI, it has been widely used in the treatment of
      amyotrophic lateral sclerosis (ALS). A 2007 Cochrane review, summarizing the findings of 4
      placebo-controlled randomized trials, concluded that at a dose of 100 mg daily, riluzole is
      safe and improves median survival by 2-3 months in patients with ALS. In regards to adverse
      events (AEs), riluzole was well tolerated, although treated patients were 2.6 times more
      likely to experience a three-fold increase in serum alanine transaminase (ALT) as compared to
      patients treated with placebo. However, this effect was found to be uniformly reversible with
      cessation of riluzole therapy and was only reported after several months of medication
      administration. Recently, the clinical safety and pharmacokinetic profile of riluzole have
      been studied in a multi-center pilot study in the context of traumatic SCI. A total of 36
      patients received an oral dose of riluzole 50 mg twice daily for 2 weeks, with treatment
      initiated within 12 hours of injury for all patients. The 12 hour dosing window, as well as
      the 2 week duration of therapy, was chosen to match the period of medication administration
      to the known period of glutamatergic excitotoxicity after SCI (several minutes after injury
      until 2 weeks after injury). With the final analysis currently undergoing peer review,
      completion of this study has confirmed the acceptable safety profile of riluzole
      administration previously documented in the ALS literature, and has established the
      feasibility of conducting a large-scale efficacy trial investigating this therapy.

      At present, there is no specific pharmacological therapy that is given uniformly to all
      patients with traumatic SCI. As a result, a placebo-controlled comparison group is ethical
      and justifiable.

      The aim of the current trial is to evaluate efficacy and safety of riluzole in the treatment
      of patients with acute SCI. The primary objective of the current Phase II/III trial is to
      evaluate the superiority of riluzole, at a dose of 2 x 100 mg the first 24 hours followed by
      2 x 50 mg for the following 13 days after injury, as compared to placebo, in change between
      180 days and baseline in motor outcomes as measured by International Standards for
      Neurological Classification of Spinal Cord Injury Examination (ISNCSCI) Motor Score, in
      patients with acute traumatic SCI, presenting to the hospital less than 12 hours after
      injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ISNCSCI Total Motor Score between 180 days and baseline</measure>
    <time_frame>180 Days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury</description>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2x in first 24 hours; Placebo 2x day 2--14</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Age between 18 and 75 years inclusive

          -  Able to cooperate in the completion of a standardized neurological examination by
             ISNCSCI standards (includes patients who are on a ventilator)

          -  Willing and able to comply with the study Protocol

          -  Signed Informed Consent Document (ICD) by patient, legal representative or witness

          -  Able to receive the Investigational Drug within 12 hours of injury

          -  ISNCSCI Impairment Scale Grade &quot;A,&quot; &quot;B&quot; or &quot;C&quot; based upon first ISNCSCI evaluation
             after arrival to the hospital

          -  Neurological Level of Injury between C4-C8 based upon first ISNCSCI evaluation after
             arrival to the hospital

          -  Women of childbearing potential must have a negative serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test or a negative urine pregnancy test

        EXCLUSION:

          -  Injury arising from penetrating mechanism

          -  Significant concomitant head injury defined by a Glasgow Coma Scale score &lt; 14 with a
             clinically significant abnormality on a head CT (head CT required only for patients
             suspected to have a brain injury at the discretion of the investigator)

          -  Pre-existent neurologic or mental disorder which would preclude accurate evaluation
             and follow-up (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric
             disorder with hallucinations and/or delusions or schizophrenia)

          -  Previous history of spinal cord injury

          -  Recent history (less than 1 year) of chemical substance dependency or significant
             psychosocial disturbance that may impact the outcome or study participation, in the
             opinion of the investigator

          -  Is a prisoner

          -  Participation in a clinical trial of another Investigational Drug or Investigational
             Device within the past 30 days

          -  Hypersensitivity to riluzole or any of its components

          -  Neutropenia measured as absolute neutrophil count (ANC) measured in cells per
             microliter of blood of &lt; 1500 at screening visit

          -  Creatinine level of &gt; 1.2 milligrams (mg) per deciliter (dL) in males or &gt; 1.1 mg per
             dL in females at screening visit

          -  Liver enzymes (ALT/SGPT or AST/SGOT) 3 times the upper limit of normal (ULN) at
             screening visit

          -  Active liver disease or clinical jaundice

          -  Acquired immune deficiency syndrome (AIDS) or AIDS-related complex

          -  Active malignancy or history of invasive malignancy within the last five years, with
             the exception of superficial basal cell carcinoma or squamous cell carcinoma of the
             skin that has been definitely treated. Patients with carcinoma in situ of the uterine
             cervix treated definitely more than 1 year prior to enrollment may enter the study

          -  Lactating at screening visit

          -  Subject is currently using, and will continue to use for the next 14 days any of the
             following medications which are classified as CYP1A2 inhibitors or inducers*:

        Inhibitors:

          -  Ciprofloxacin

          -  Enoxacin

          -  Fluvoxamine

          -  Methoxsalen

          -  Mexiletine

          -  Oral contraceptives

          -  Phenylpropanolamine

          -  Thiabendazole

          -  Zileuton

        Inducers:

          -  Montelukast

          -  Phenytoin

               -  Note: no washout period required; if these medications are discontinued, subjects
                  are eligible to be enrolled in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fehlings, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Branko Kopjar, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James D Guest, MD, PhD</last_name>
      <phone>305-243-7144</phone>
      <email>jguest@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>George Jimsheleishvili</last_name>
      <phone>(305) 243-0126</phone>
      <email>gxj150@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James D Guest, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaina Williams</last_name>
      <phone>404-778-1845</phone>
      <email>alaina.williams@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Faiz Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Arnold, MD</last_name>
      <phone>913-558-7587</phone>
      <email>parnold@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Jianas</last_name>
      <phone>(913) 558-3252</phone>
      <email>ljianas@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxwell Boakye, MD</last_name>
      <phone>502-581-8675</phone>
      <email>max.boakye@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori J Clark</last_name>
      <phone>(502) 333-8140</phone>
      <email>LoriClark2@KentuckyOneHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maxwell Boakye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason D. Wilson, MD, MS</last_name>
      <phone>504-568-2646</phone>
      <email>jwils8@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin S. Fannin, MSPH</last_name>
      <phone>504-568-2641</phone>
      <email>efanni@lsuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Wilson, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bizhan Aarabi, MD</last_name>
      <phone>410-328-7371</phone>
      <email>baarabi@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charlene Aldrich, RN, MSN</last_name>
      <phone>(410) 328-5332</phone>
      <email>caldrich@som.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bizhan Aarabi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audi Chokkalingam, CCRP</last_name>
      <phone>507-293-7392</phone>
      <email>Chokkalingam.Avudaiappan@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Nassr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Koester</last_name>
      <phone>314-362-7368</phone>
      <email>koesterl@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Zack Ray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Schuster, MD</last_name>
      <phone>215-615-4587</phone>
      <email>schustej@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francis Quattrone</last_name>
      <phone>(215) 615-4587</phone>
      <email>francis.quattrone@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Harrop, MD</last_name>
      <phone>215-955-7000</phone>
      <email>james.harrop@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Maleszewski, MS</last_name>
      <email>patrick.maleszewski@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Harrop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Hochheimer, MD</last_name>
      <phone>210-916-7624</phone>
      <email>sven.m.hochheimer.mil@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Amy E. Guthrie</last_name>
      <phone>(210) 275-8108</phone>
      <email>amy.e.guthrie.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Sven Hochheimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl M Schmitt, MD</last_name>
      <phone>713-704-7100</phone>
      <email>karl.schmitt@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elena E Viverette</last_name>
      <phone>(713) 500-6230</phone>
      <email>elena.e.viverette@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karl M Schmitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrel Brodke, MD</last_name>
      <phone>801-587-5450</phone>
      <email>darrel.brodke@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Neese</last_name>
      <email>ashley.neese@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Darrel Brodke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Shaffrey, MD</last_name>
      <phone>434-243-9728</phone>
      <email>CIS8Z@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Judy Beenhakker, MS</last_name>
      <phone>(434) 982-1856</phone>
      <email>JGB3P@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Shaffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathaniel Brooks Brooks, MD</last_name>
      <phone>608-263-1410</phone>
      <email>n.brooks@neurosurgery.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Wilbrand</last_name>
      <phone>(608) 265-9248</phone>
      <email>s.wilbrand@neurosurgery.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nathaniel Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shekar Kurpad, MD</last_name>
      <phone>414-805-5978</phone>
      <email>skurpad@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Klis</last_name>
      <phone>(414) 805-7183</phone>
      <email>cklis@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shekar Kurpad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt J. Balogh, MD, PhD</last_name>
      <phone>+61 2 4921 4259</phone>
      <email>zsolt.balogh@hnehealth.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Kate King</last_name>
      <phone>+61 2 4921 4970</phone>
      <email>kate.king@hnehealth.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Zsolt J. Balogh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trent Li</last_name>
      <phone>+61 0430861828</phone>
      <email>trent.li@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Ralph Stanford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Rehab</name>
      <address>
        <city>Ryde</city>
        <state>New South Wales</state>
        <zip>2112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trent Li</last_name>
      <phone>+61 0430861828</phone>
      <email>trent.li@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Jonathon Ball, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Freeman, MD</last_name>
      <phone>+61 882224466</phone>
      <email>brian.freeman@health.sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>James Swift</last_name>
      <phone>+ 61 8 7074 1544</phone>
      <email>James.Swift@sa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leilani Reichl</last_name>
      <phone>(604) 875 4111</phone>
      <phone_ext>62853</phone_ext>
      <email>Leilani.Reichl@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Brian K Kwon, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Yee, MD</last_name>
      <phone>(416) 480-6815</phone>
      <email>albert.yee@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Aimee Theriault</last_name>
      <phone>(416) 480-4285</phone>
      <email>aimee.theriault@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Albert Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayee Tung, RN, CCRP</last_name>
      <phone>(416) 864-6060</phone>
      <email>TungK@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Jefferson Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fehlings, MD</last_name>
      <phone>(416) 603-5627</phone>
      <email>Michael.Fehlings@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Yuriy Petrenko, MD</last_name>
      <phone>(416) 603-5285</phone>
      <email>yuriy.petrenko@uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Fehlings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alpesh Patel, MD</last_name>
      <phone>+64 9 276 0000</phone>
      <email>alpesh.patel@middlemore.co.nz</email>
    </contact>
    <contact_backup>
      <last_name>Jo Nunnerley</last_name>
      <phone>+64 3 383 6871</phone>
      <email>jo.nunnerley@burwood.org.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Alpesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kris Dalzell, MD</last_name>
      <phone>+64 3 365 3376</phone>
      <email>kristian.dalzell@cdhb.health.nz</email>
    </contact>
    <contact_backup>
      <last_name>Jo Nunnerley</last_name>
      <phone>+64 3 383 6871</phone>
      <email>jo.nunnerley@burwood.org.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Kris Dalzell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aospine.org</url>
    <description>AOSpine North America is a non for profit foundation for excellence in spine</description>
  </link>
  <reference>
    <citation>Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Harkema SJ, Guest JD, Tator CH, Burau KD, Johnson MW, Grossman RG. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. J Neurosurg Spine. 2012 Sep;17(1 Suppl):151-6. doi: 10.3171/2012.4.AOSPINE1259.</citation>
    <PMID>22985381</PMID>
  </reference>
  <reference>
    <citation>Fehlings MG, Wilson JR, O'Higgins M. Introduction: Spinal cord injury at the cutting edge of clinical translation: a focus issue collaboration between NACTN and AOSpine North America. J Neurosurg Spine. 2012 Sep;17(1 Suppl):1-3. doi: 10.3171/2012.6.AOSPINE12632.</citation>
    <PMID>22985363</PMID>
  </reference>
  <reference>
    <citation>Wilson JR, Forgione N, Fehlings MG. Emerging therapies for acute traumatic spinal cord injury. CMAJ. 2013 Apr 2;185(6):485-92. doi: 10.1503/cmaj.121206. Epub 2012 Dec 10. Review. Erratum in: CMAJ. 2014 Mar 4;186(4):294.</citation>
    <PMID>23228995</PMID>
  </reference>
  <reference>
    <citation>Grossman RG, Fehlings MG, Frankowski RF, Burau KD, Chow DS, Tator C, Teng A, Toups EG, Harrop JS, Aarabi B, Shaffrey CI, Johnson MM, Harkema SJ, Boakye M, Guest JD, Wilson JR. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014 Feb 1;31(3):239-55. doi: 10.1089/neu.2013.2969. Epub 2013 Oct 11.</citation>
    <PMID>23859435</PMID>
  </reference>
  <reference>
    <citation>Nagoshi N, Fehlings MG. Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II. Expert Opin Investig Drugs. 2015 May;24(5):645-58. doi: 10.1517/13543784.2015.1009629. Epub 2015 Feb 3. Review.</citation>
    <PMID>25645889</PMID>
  </reference>
  <reference>
    <citation>Nagoshi N, Nakashima H, Fehlings MG. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules. 2015 Apr 29;20(5):7775-89. doi: 10.3390/molecules20057775. Review.</citation>
    <PMID>25939067</PMID>
  </reference>
  <reference>
    <citation>Fehlings MG, Nakashima H, Nagoshi N, Chow DS, Grossman RG, Kopjar B. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord. 2016 Jan;54(1):8-15. doi: 10.1038/sc.2015.95. Epub 2015 Jun 23.</citation>
    <PMID>26099215</PMID>
  </reference>
  <results_reference>
    <citation>Chow DS, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Johnson MM, Boakye M, Frankowski RF, Fehlings MG, Grossman RG. Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine. 2012 Sep;17(1 Suppl):129-40. doi: 10.3171/2012.5.AOSPINE12112.</citation>
    <PMID>22985379</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson JR, Fehlings MG. Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy. World Neurosurg. 2014 May-Jun;81(5-6):825-9. doi: 10.1016/j.wneu.2013.01.001. Epub 2013 Jan 4. Review.</citation>
    <PMID>23295632</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Riluzole</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

